[go: up one dir, main page]

ATE468886T1 - Abeta-bindende moleküle - Google Patents

Abeta-bindende moleküle

Info

Publication number
ATE468886T1
ATE468886T1 AT04708962T AT04708962T ATE468886T1 AT E468886 T1 ATE468886 T1 AT E468886T1 AT 04708962 T AT04708962 T AT 04708962T AT 04708962 T AT04708962 T AT 04708962T AT E468886 T1 ATE468886 T1 AT E468886T1
Authority
AT
Austria
Prior art keywords
abeta
binding molecules
murine antibody
antibodies
syndrome
Prior art date
Application number
AT04708962T
Other languages
English (en)
Inventor
Julian Davies
Ying Tang
Jeffry Watkins
Original Assignee
Applied Molecular Evolution
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Molecular Evolution filed Critical Applied Molecular Evolution
Application granted granted Critical
Publication of ATE468886T1 publication Critical patent/ATE468886T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04708962T 2003-02-10 2004-02-06 Abeta-bindende moleküle ATE468886T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44638003P 2003-02-10 2003-02-10
PCT/US2004/002004 WO2004071408A2 (en) 2003-02-10 2004-02-06 Aβ BINDING MOLECULES

Publications (1)

Publication Number Publication Date
ATE468886T1 true ATE468886T1 (de) 2010-06-15

Family

ID=32869500

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04708962T ATE468886T1 (de) 2003-02-10 2004-02-06 Abeta-bindende moleküle

Country Status (6)

Country Link
US (3) US7575747B2 (de)
EP (1) EP1596809B1 (de)
AT (1) ATE468886T1 (de)
DE (1) DE602004027348D1 (de)
ES (1) ES2344645T3 (de)
WO (1) WO2004071408A2 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US20060024667A1 (en) * 2004-07-29 2006-02-02 Karen Manucharyan Compositions and methods for Alzheimer's disease
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
JP5475994B2 (ja) 2005-11-30 2014-04-16 アッヴィ・インコーポレイテッド 抗Ａβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。
KR101439828B1 (ko) 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
SG10201404801YA (en) * 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
TR201802814T4 (tr) * 2006-07-14 2018-03-21 Ac Immune Sa Amiloid betaya karşı insanlaştırılmış antikor.
AR062065A1 (es) * 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
US20090053210A1 (en) 2006-09-01 2009-02-26 Roland Buelow Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
AU2008206555B2 (en) * 2007-01-18 2013-07-04 Eli Lilly And Company Pegylated Abeta Fab
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EA200901140A1 (ru) 2007-03-01 2010-04-30 Пробиодруг Аг Новое применение ингибиторов глутаминилциклазы
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
SG182192A1 (en) * 2007-06-12 2012-07-30 Ac Immune Sa Humanized antibodies to amyloid beta
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
SG178809A1 (en) * 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
PT2238166E (pt) 2007-10-05 2014-02-11 Genentech Inc Utilização do anticorpo anti-amilóide beta em doenças oculares
EP2205631B1 (de) * 2007-10-05 2016-11-23 Genentech, Inc. Methoden und zusammensetzungen zur diagnose und behandlung von amyloidose
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
AR069610A1 (es) 2007-12-11 2010-02-03 Glaxo Group Ltd Proteinas de union a antigenos que se unen al peptido beta-amiloide
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN102695546B (zh) 2009-09-11 2014-09-10 前体生物药物股份公司 作为谷氨酰胺酰环化酶抑制剂的杂环衍生物
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
MX341369B (es) 2010-07-30 2016-08-17 Genentech Inc * Anticuerpo anti-beta-amiloide humanizado seguro y funcional.
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
EP4331605A3 (de) 2013-09-13 2024-05-22 F. Hoffmann-La Roche AG Verfahren und zusammensetzungen mit gereinigten rekombinanten polypeptiden
JP6546178B2 (ja) 2013-09-13 2019-07-17 ジェネンテック， インコーポレイテッド 細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法
US10323067B2 (en) * 2014-05-14 2019-06-18 Evorx Technologies, Inc. Methods and compositions for controlling gene expression and treating cancer
CN116063375A (zh) 2015-08-21 2023-05-05 豪夫迈·罗氏有限公司 在亲和层析中减少宿主细胞蛋白的方法
CA3004494A1 (en) 2015-11-09 2017-05-18 The University Of British Columiba Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
KR20180094876A (ko) 2015-11-09 2018-08-24 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 에피토프 및 이에 대한 항체
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
AU2017299858B2 (en) 2016-07-18 2024-07-25 Promis Neurosciences, Inc. Antibodies to Amyloid beta
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
JP7330164B2 (ja) 2017-07-18 2023-08-21 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータに対する抗体
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
EP3658172A4 (de) 2017-07-25 2021-05-05 TrueBinding, Inc. Behandlung von krebs durch blockierung der interaktion von tim-3 und seinem liganden
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
US12325741B2 (en) 2018-07-17 2025-06-10 Jiangsu Hengrui Medicine Co., Ltd. Anti-Aβ antibodies and antigen-binding fragments thereof
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US5278049A (en) * 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5837672A (en) * 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
WO1995020979A1 (en) * 1994-02-03 1995-08-10 The Picower Institute For Medical Research Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US6114133A (en) * 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
JPH09292571A (ja) * 1996-04-26 1997-11-11 Nikon Corp 顕微鏡対物レンズ
US6218506B1 (en) * 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6413940B1 (en) 1997-02-07 2002-07-02 Nymox Corporation Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS
US20020086847A1 (en) * 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
EP2006303A1 (de) 1997-04-09 2008-12-24 Intellect Neurosciences, Inc. Beta-Amyloid-Enden-spezifische rekombinante Antikörper, DNS-Codierung und Verwendungsverfahren
US6787319B2 (en) * 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
JP2001512689A (ja) * 1997-08-11 2001-08-28 カイロン コーポレイション Ｔ細胞を遺伝子改変するための方法
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
EP1078005B1 (de) 1998-05-21 2010-04-21 University Of Tennessee Research Foundation Methoden zur amyloidentfernung mit anti-amyloid-antikörper
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
DK1409654T3 (da) * 1999-06-16 2008-12-08 Boston Biomedical Res Inst Immunologisk styring af beta-amyloid-niveauer in vivo
DE60043165D1 (de) 1999-08-04 2009-11-26 Univ Southern California Globularer Aufbau vom Amyloid-beta- protein und deren Verwendungen
US6919075B1 (en) 1999-09-03 2005-07-19 Ramot At Tel Aviv University Ltd. Bacteriophage displaying aβ epitopes and method of use
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
DE1257584T1 (de) 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
US20020009445A1 (en) * 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
DE60139788D1 (de) 2000-09-06 2009-10-15 Aventis Pharma Sa Verfahren und zusammensetzungen für amyloidosis-verbundene krankheiten
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
AU2002257162A1 (en) * 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
DK1944040T3 (da) * 2001-08-17 2012-10-29 Univ Washington Analysefremgangsmåde for Alzheimers sygdom
DK1416965T3 (da) 2001-08-17 2008-05-05 Univ Washington Assayfremgangsmåde til Alzheimers sygdom
CA2452104A1 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
US20040192898A1 (en) * 2001-08-17 2004-09-30 Jia Audrey Yunhua Anti-abeta antibodies
EP1519740A4 (de) 2001-08-17 2005-11-09 Lilly Co Eli Schnelle verbesserung der kognition bei erkrankungen im zusammenhang mit a-beta
US7166478B2 (en) * 2002-03-12 2007-01-23 Enzo Life Sciences, Inc., C/O Enzo Biochem, Inc. Labeling reagents and labeled targets, target labeling processes and other processes for using same in nucleic acid determinations and analyses
AU2003223474B2 (en) 2002-04-25 2008-09-04 Eli Lilly And Company Method for treating anxiety and mood disorders in older subjects

Also Published As

Publication number Publication date
EP1596809A4 (de) 2007-10-24
ES2344645T3 (es) 2010-09-02
EP1596809B1 (de) 2010-05-26
US8105597B2 (en) 2012-01-31
US8623365B2 (en) 2014-01-07
US20060110388A1 (en) 2006-05-25
WO2004071408A3 (en) 2007-04-12
WO2004071408A2 (en) 2004-08-26
DE602004027348D1 (de) 2010-07-08
US20090297505A1 (en) 2009-12-03
US20120114560A1 (en) 2012-05-10
EP1596809A2 (de) 2005-11-23
US7575747B2 (en) 2009-08-18

Similar Documents

Publication Publication Date Title
ATE468886T1 (de) Abeta-bindende moleküle
MX2022005782A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos.
WO2004044204A3 (fr) Fragments variables d'anticorps de camelides a chaine unique et leurs applications pour le diagnostic et le traitement de pathologies diverses.
WO2003016466A3 (en) ANTI-Aβ ANTIBODIES
NO20074563L (no) Novel anti-plgf antibody
HUP0302589A2 (hu) A béta-amiloid peptidet felismerő humanizált ellenanyagok
BR0315157A (pt) Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
DK1613347T3 (da) Humaniserede antistoffer, der genkender beta-amyloidpeptid
ATE461220T1 (de) Anti-egfr-antikörper
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
WO2006121560A3 (en) Methods and compositions for treatment of cns disorders
ATE409047T1 (de) Humanisierte antikörper
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
NO20053435L (no) Immunoglobulinvarianter og anvendelser derav
WO2006040153A3 (en) Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
AU2002258808A1 (en) Humanized antibodies
PL2004688T3 (pl) Ulepszone przeciwciała wobec protofibryli oraz ich zastosowania
MX2009001110A (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos.
EA200401170A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
WO2008140653A3 (en) Humaneered anti-factor b antibody
WO2006096489A3 (en) Anti-m-csf antibody compositions having reduced levels of endotoxin
WO2005028498A3 (en) Kid3 and kid3 antibodies that bind thereto

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties